Resource Center

Go back to Resource Center

Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).

2014 Mar

Journal Article

Authors:
Atallah, E.; Bylow, K.; Troy, J.; Saber, W.

Secondary:
Curr Hematol Malig Rep

Volume:
9

Pagination:
57-65

Issue:
1

PMID:
24398726

DOI:
10.1007/s11899-013-0195-9

Keywords:
Age Factors; Aged; Comorbidity; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes

Abstract:
MDS are myeloid clonal hematologic disorders that are most commonly diagnosed in the seventh decade of life. Several treatment options are currently available. However, allo HSCT remains the only curative therapy. Unfortunately, despite the higher incidence of MDS in the older population, less than 10 % of patients undergoing allo HSCT for MDS are > 65 years old. In this paper we discuss the various treatment options in older patients with high-risk MDS with particular emphasis on the role of allo HSCT in older MDS patients.

Go back to Resource Center